• Biomolecules & Therapeutics
• /
• 제12권2호
• /
• pp.85-91
• /
• 2004

In all attempt to elucidate the role of apoptosis in drug resistance, cisplatin-resistant human chronic myelogenous leukemia (CML) K562 cells (K562/CDDP) were established and compared with drug sensitive parent cells (K562) in the induction of apoptosis. K562/CDDP cells were 5-fold more resistant to cisplatin compared to K562 cells. In addition, K562/CDDP cells were significantly more resistant to apoptois as judged by DNA fragmentation and DAPI staining. K562/CDDP cells exhibited decreased proleolytic activity of caspase-3 and this was further demonstrated by decreased cleavage of its substrate poly (ADP-ribose) polymerase (PARR- Western blot analysis showed that K562/CDDP cells had longer sustained levels of BCL-$X_L$ whereas no difference was noted in the level of Bcl-2. the translocation of Bax to mitochondria was significantly delayed in K562/CDDP cells. These results suggest that the reduced translocation of Bax and the sustained expression of BCL-$X_L$ may cause resistance to apoptosis through prevention of mitochondria release of cytochrome c, which subsequently induces reduction of caspase-3 activity and that this response is partly responsible for the acquired resistance to cisplatin ill K562 cells.

• IMMUNE NETWORK
• /
• 제6권4호
• /
• pp.179-184
• /
• 2006

Background: Identification of antigen-specific T cells has yielded valuable information on pathologic process and the disease state. Assays for quantification of inflammatory cytokines or lytic-granule molecules have been generally used to evaluate antigen specific T cell response, however their applicability have been hampered due to the limited source of autologous antigen-presenting target cells (APC). Methods: K562, a leukemic cell line deficient of human leukocyte antigen (HLA), was transfected with a gene encoding HLA-A*02 (K562/ A*02) and its function as stimulator cells in inducing activation of HLA-matched T cells was evaluated by IFN-${\gamma}$ enzyme linked immunospot (ELISPOT) assay. Results: The stable transfectant K562/ A*02 pulsed with HLA- A*02 restricted peptide could specifically induce IFN-${\gamma}$ secretion by CD8+ T cells compared to no detectable secretion by CD4+ T cells. However, CD56+ NK cells secreted IFN-${\gamma}$ in both K562/ A*02 with peptide and without peptide. The number of IFN-${\gamma}$ secreted CD8+ T cells was increased according to the ratio of T cells to K562 and peptide concentration. Formalin-fixed K562/ A*02 showed similar antigen presenting function to live K562/ A*02. Moreover, K562/ A*02 could present antigenicpeptide to not only A*0201 restricted CD8+ T cells but also CD8+ T cells from A*0206 donor. Conclusion: These results suggest that K562/ A*02 could be generally used as target having specificity and negligible background for measuring CD8+ T cell responses and selective use of K562 with responsder matched HLA molecules on its surface as APC may circumvent the limitation of providing HLA-matched autologous target cells.

• IMMUNE NETWORK
• /
• 제7권2호
• /
• pp.80-86
• /
• 2007

Background: CD40-activated B (CD40-B) cells might be an attractive source of autologous antigen-presenting cells (APCs) for immunotherapy due to the convenience to obtain from peripheral blood and expand in vitro. Moreover, CD40-B cells were found to be comparable with DCs in their capacity to raise antigen-specific CD8+ T cells. Here, we have established K562 cells expressing CD40L to expand CD40-activated B cells used for APCs. Methods: After activation of B cell by K562/CD40L, CD40-B cells were examined by counting B cell numbers. Surface expression of CD54, CD80, CD86 and HLA class II was measured by flow cytometry. The CD40-B cells were tested for its function as APC by mixed lymphocyte reactions (MLR) and by induction of T cell responses specific for pp65 peptide in vitro. Results: The expansion of B cells by K562/CD40L increased about 6-folds compared with anti-CD40 or K562. Furthermore, the expression of CD54, CD80, CD86 and HLA class II was up-regulated by K562/CD40L. B cells by K562/CD40L showed comparable antigen presentation activity with mature DCs as shown in MLR, INF-${\gamma}$ ELISPOT assay. Conclusion: These results suggest that K562/CD40L could be used to generate activated B cells as potent APCs which could be useful for cellular vaccination and adoptive immunotherapy.

• 한국동물학회지
• /
• 제39권1호
• /
• pp.12-20
• /
• 1996

K562 적혈구암 세포는 phorbol 12-myristate 13-acetate(PMA)에 의해서 대핵세포로 분화되고 gpIlla의 증가, megakaryocyte와 유사한 형태학적 변화로 특징지워진다. 또한 K562 세포는 dimethy1 sulfoxide(DMSO)나 butyrate와 같은 화학적 유도원에 의해 적혈구로 분화가 유도되고 동시에 헤모글로빈이 축척된다. 본 연구에서는 K562 세포에 대한 단일클론 항체를 생성하고 이를 이용하고 61 KDa의 표면항원을 동정하였다. 단클론항체 EK-2에 의해 인지되는 61 KDa의 표면항원은 sialic acide가 풍부해 당단백질로 사료되고, 그 epitope는 neuraminidase 절단과 peroxidase oxidation에 민감하며, 열처리에는 안정하다. K562 세포의 대핵세포로 분화시에는 61 KDa 표면항원의 발현은 증가하며, 적혈구로 분회시에는 그 발현이 감소한다. EK-2 단클론항체는 조혈세포의 분화 및 암화과정의 분자적 수준을 연구하기 위한 면역학적 probe로 이용 가능할 것으로 기대된다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제26권3호
• /
• pp.145-155
• /
• 2022

Multidrug resistance of tumors has been a severe obstacle to the success of cancer chemotherapy. The study wants to investigate the reversal effects of imperatorin (IMP) on doxorubicin (DOX) resistance in K562/DOX leukemia cells, A2780/Taxol cells and in NOD/SCID mice, to explore the possible molecular mechanisms. K562/DOX and A2780/Taxol cells were treated with various concentrations of DOX and Taol with or without different concentrations of IMP, respectively. K562/DOX xenograft model was used to assess anti-tumor effect of IMP combined with DOX. MTT assay, Rhodamine 123 efflux assay, RT-PCR, and Western blot analysis were determined in vivo and in vitro. Results showed that IMP significantly enhanced the cytotoxicity of DOX and Taxol toward corresponding resistance cells. In vivo results illustrated both the tumor volume and tumor weight were significantly decreased after 2-week treatment with IMP combined with DOX compared to the DOX alone group. Western blotting and RT-PCR analyses indicated that IMP downregulated the expression of P-gp in K562/DOX xenograft tumors in NOD/SCID mice. We also evaluated glycolysis and glutamine metabolism in K562/DOX cells by measuring glucose consumption and lactate production. The results revealed that IMP could significantly reduce the glucose consumption and lactate production of K562/DOX cells. Furthermore, IMP could also remarkably repress the glutamine consumption, α-KG and ATP production of K562/DOX cells. Thus, IMP may sensitize K562/DOX cells to DOX and enhance the antitumor effect of DOX in K562/DOX xenograft tumors in NOD/SCID mice. IMP may be an adjuvant therapy to mitigate the multidrug resistance in leukemia chemotherapy.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권21호
• /
• pp.9131-9136
• /
• 2014

ELDF15, homologous with AT2 receptor-interaction protein 1 (ATIP1), may play an important role in cell differentiation, proliferation, and carcinogenesis. We aimed to understand the biological function of ELDF15 via construction and transfection of a recombinant expression vector containing antisense ELDF15. Recombinant expression vectors were successfully constructed and transfected into K562 cells. A stable transfectant, known as pXJ41-asELDF15, stably produced antisense ELDF15. Compared with K562 and K562-zeo cells, K562-pXJ41-asELDF15 cells showed inhibition of cell proliferation. RT-PCR analysis showed that the expression and protein level of ELDF15 decreased significantly in K562 cells transfected with pXJ41-asELDF15. Expression of hemoglobin increased in K562 cells transfected with pXJ41-asELDF15 by benzidine staining. increases NBT reduction activity in K562 cells transfected with pXJ41-asELDF15.Colony forming efficiency in two-layer soft agar was clearly inhibited as assessed by electron microscopy. These results suggest that ELDF15 plays a potential role in cell differentiation, proliferation and carcinogenesis.

• 생명과학회지
• /
• 제23권2호
• /
• pp.197-206
• /
• 2013

본 연구에서는 K562 만성 골수성 백혈병 세포를 이용하여, 분화 유도에 의해 암 유지/개시 세포의 자기 재생능력이 소실되는 지를 조사하였다. K562 세포의 집락(colony) 형성 능력은 PMA 처리에 의하여 현저히 억제되었고, 1 nM 이상의 PMA 처리시에는 집락이 형성되지 않았으나, 약 40%의 세포는 여전히 연한천(soft agar)에서 살아 있었다. PMA 4 nM을 3일간 처리하고 제거한 후 분리한 집락 형성 세포에 다시 10 nM PMA를 3일간 처리하였을 때, 약 70% 정도의 세포가 분화되었고, 6주 후에 PMA를 처리하였을 때는 분화율이 약 90%로 K562 모세포에 PMA를 처리한 수준에 도달하였다. 한편, imatinib-내성 K562 변종 세포들은 연한천에서 집락을 형성하지 않았으며, 대부분의 세포가 CD44 양성이었다. Imatinib 무첨가 배지에서 4개월 배양 후, 이 세포들의 표면 CD44발현량은 감소하였고, K562/R3 imatinib-내성 변종 세포에서는 연한천에서 작은 집락이 형성되었다. 이 세포에서는 imatinib-내성 변종 세포에서 소실되었던 Bcr-Abl이 다시 발현되기 시작하였고, 다른 표현형들도 부분적으로 회복되었다. 이러한 결과는 백혈병 유지 세포가 분화에 내성을 나타내는 세포이며, 분화 유도제를 오랜 기간 동안 고농도로 처리할 수 있다면 백혈병 줄기 세포를 제거하기 위한 분화 요법이 백혈병 치료에 적용될 수 있음을 시사하였다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권12호
• /
• pp.7501-7508
• /
• 2013

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder of hematopoietic stem cell scarrying the Philadelphia (Ph) chromosome and an oncogenic BCR-ABL1 fusion gene. The tyrosine kinase inhibitor (TKI) of BCR-ABL1 kinase is a treatment of choice for control of CML. Objective: Recent studies have demonstrated that miRNAs within exosomes from cancer cells play crucial roles in initiation and progression. This study was performed to assess miRNAs within exosomes of K562 cells. Methods: miRNA microarray analysis of K562 cells and K562 cell-derived exosomes was conducted with the 6th generation miRCURYTM LNA Array (v.16.0). Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were also carried out. GO terms and signaling pathways were categorized into 66 classes (including homophilic cell adhesion, negative regulation of apoptotic process, cell adhesion) and 26 signaling pathways (such as Wnt). Results: In exosomes, 49 miRNAs were up regulated as compared to K562 cells, and two of them were further confirmed by quantitative real-time PCR. There are differentially expressed miRNAs between K562 cell derived-exosomes and K562 cells. Conclusion: Selectively expressed miRNAs in exosomes may promote the development of CML via effects on interactions (e.g. adhesion) of CML cells with their microenvironment.

• 대한임상검사과학회지
• /
• 제39권2호
• /
• pp.68-75
• /
• 2007

약 100년 전에 박테리아가 암을 억제한다는 보고를 바탕으로 다양한 미생물이 항암효과를 가지는 백신 개발에 이용되거나 또는 미생물의 세포 밖 독소 단백질을 찾아내고 있다. Psuedomonas aeruginosa exotoxin A(ETA)는 암세포에서 세포성장을 억제하고 세포 죽음을 유발하는 것으로 알려져 있다. 하지만 ETA가 세포 자멸사를 유도하는 정확한 기전은 아직 알려져 있지 않다. 따라서 본 연구에서는 세포자멸사의 유도를 확인하기 위해 K562 cell을 이용하여 세포의 형태학적 변화, 세포독성, Annexin-V binding assay 그리고 세포주기를 분석하였으며, 그 결과로 ETA는 K-562세포에서의 세포증식과 성장을 억제하였고, 세포자멸사 기작을 통한 K-562 암세포의 사멸을 일으켰음을 관찰하였다. 또한 flow cytometric analysis에서는 ETA가 세포주기 중 특히 sub-G1 기를 정지시키는 것으로 나타났다. 본 연구는 ETA가 인간 백혈병 K-562 암세포의 세포성장을 억제하고 sub-G1 기를 정지시킴으로서 세포자멸사를 유도하고 있음을 확인하였다.

• Archives of Pharmacal Research
• /
• 제19권5호
• /
• pp.416-422
• /
• 1996

Twenty one phenylacetylshikonin analogues were synthesized from various subsitituted phenyl acetic acids and their cytotoxicity values against A549, K562 and L1210 cell lines and antitumor action in mice bearing S-180 cells were measured. All of phenylacetylshikonin analogues expressed a potent cytotoxicity $(ED_{50}, 0.1-1.80{\mu}g/ml)$ against L1210 and K562 cells. L1210 cells were the most sensitive to shikonin analogues among these cells. Except 4-methosyphenylacetylshikonin $(0.098 {\mu}g/ml)$, and a-acetoxyphenylacetylshikonin $(0.10 {\mu}g/ml)$, all other shikonin derivatives sshowed higher $ED_{50}$ values than phenylacetylshikonin $(0.13{\mu}g/ml)$, in L1210. In K562 cell, a-substitution of phenylacetylshikonin $(0.1{\mu}g/ml)$, while other subsitutions increased it slightly; 4-methoxyphenylacetylshikonin $(0.033{\mu}g/ml)$ showed a exceptionally good cytotoxicity against K562 cell. 4-Halogenation tended to decrease the cytotoxic effect on L1210 cells, while it enhanced the effect on K562; 4-bromophenylacetyl $$[ED_{50};(L1210)=1.76{\mu}g/ml, ;ED_{50};(K 562)=0.32 {\mu}g/ml]$$ and 4-chlorophenylacetyl shikonin $$[ED_{50};(L1210)=1.64 {\mu}g/ml, ;ED_{50};(K562)=0.32 {\mu}g/ml]$$. In contrast, A549 cells were much less sensitive to these shikonin analogues which showed $ED_{50}$ values of$1.5-1.35 {\mu}g/ml)$.Most of phenylacetylshikonin derivatives showed good antitumor activity in mice bearing S-180 cells. a-A-cetoxyphenylacetylshikonin and 4-dimethylaminophenylacetylshikonin showed highest T/C value (192-195%), implying that introduction of a-acetyl or of 4-dimethylamino group enhanced the antitumor activity as shown for 4-dimethylaminophenylacetylshikonin (T/C, 192%). It might be due to improvement of water solubility by dimethylamino group in the molecule.